Showing 1671 - 1680 of 1708 for "Copyright & related rights" with applied filters
Filters:
31 August 2018 by Özge Atilgan Karakulak
Özge Atılgan Karakulak and Güldeniz Doğan Alkan of Gün + Partners examine the advantages and disadvantages of TÜRKSMD, a new company set up by the Turkish IP Office to value intellectual property rights
02 July 2018 by Managing Intellectual Property
In Mexico, droit moral is attached to the author and is inalienable, does not expire, cannot be waived and cannot be encumbered. The author and his/her heirs can enforce this right.
The general limitation period for juridical actions in Austria is 30 years. However, particular laws can stipulate shorter or longer limitation periods.
02 July 2018 by Editha Hechanova
All government agencies such as the Intellectual Property Office of the Philippines (IPOPHL) are directed to promote the use of alternative dispute resolution (ADR) in resolving disputes and cases.
CRISPR technology enables genes to be edited and can eventually treat diseases caused by gene mutations.
02 July 2018 by Takanori Abe
Shionogi is the owner of a patent entitled Pyrimidine Derivatives (JP2648897). X filed a request for a trial for invalidation of the patent. Nippon Chemiphar intervened in the trial as a plaintiff, and AstraZeneca UK intervened in the trial in order to support the defendant.
02 July 2018 by Aurélia Marie
In France, a prior right holder cannot oppose a trade mark based on bad faith.
02 July 2018 by Lucy Songi
Lucy Songi speaks to leading female practitioners from De Clercq & Partners, Properta Attorneys, Spoor & Fisher and Gowling WLG about their experiences in IP and advice for women considering a career in this field
In a recent ruling by the Court of The Hague (ECLI:NL:RBDHA:2018:4591) a defendant/patentee has been ordered to pay the costs of nullity proceedings brought against it, despite not wishing to maintain or assert its patent.
02 July 2018 by Sybille Pfender
At the end of April 2018, Advocate General (AG) Wathelet handed down an advisory opinion regarding the first of three recent referrals to the CJEU (C-121/17). This concerns the interpretation of Article 3(a) of Regulation (EC) No 469/2009.
